Effects of Dan Shen ( Salvia miltiorrhiza ) on blood pressure management in hypertensive patients: a randomized controlled trial

作者：Pan Li, Zonghua Jiang, Linfei Dong, Shifeng Wang, Jiangli Qi, Longhong Zhu · 发表于：Blood Pressure · 年份：2025 · DOI：10.1080/08037051.2025.2532523 · 被引用次数：2 · 研究领域：Antioxidants, Aging, Portulaca oleracea、Traditional Chinese Medicine Studies、Traditional Chinese Medicine Analysis

Objective This randomized, double-blind, placebo-controlled trial aimed to evaluate the efficacy and safety of Salvia miltiorrhiza (Dan Shen) in the management of primary hypertension.Methods From April 2023 to September 2024, 320 patients aged 30–75 years with diagnosed primary hypertension were enrolled at Ganzhou Hospital of Southern Medical University (Ganzhou People's Hospital). Patients were randomized to receive either intravenous Salvia miltiorrhiza (20 mL diluted in 200 mL of 5% glucose daily for 12 weeks) or a placebo with identical appearance and administration. Primary outcomes included changes in blood pressure measured by 24-hour ambulatory blood pressure monitoring (ABPM). Secondary outcomes included symptom scores, lipid and glucose profiles, and health-related quality of life assessed using validated laboratory measures and the SF-36 questionnaire.Results A significant reduction in systolic and diastolic blood pressure was observed in the intervention group from week 4, reaching 136.78 ± 10.28 mmHg and 85.36 ± 8.37 mmHg by week 12, respectively—both significantly lower than in the control group (p < 0.01). Symptom scores for headache, dizziness, and fatigue decreased by 1.2, 1.1, and 1.2 points (p < 0.01), with no significant changes in the control group. Lipid profiles improved notably: total cholesterol, LDL-C, and triglycerides declined by 9.8%, 10.7%, and 17.1%, respectively, while HDL-C increased by 17.0% (all p < 0.05). Fasting glucose levels fell by 4....